标题
Immune checkpoint therapy—current perspectives and future directions
作者
关键词
-
出版物
CELL
Volume 186, Issue 8, Pages 1652-1669
出版商
Elsevier BV
发表日期
2023-04-14
DOI
10.1016/j.cell.2023.03.006
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
- (2022) Thomas Powles et al. NATURE MEDICINE
- T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
- (2022) Alexander X. Lozano et al. NATURE MEDICINE
- Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
- (2022) Vicky Makker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
- (2022) Yuichiro Doki et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment
- (2022) Klaire Yixin Fjæstad et al. ONCOGENE
- Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target
- (2022) Nourhan Abdelfattah et al. Nature Communications
- Hallmarks of Cancer: New Dimensions
- (2022) Douglas Hanahan Cancer Discovery
- Intratumor Microbiome Analysis Identifies Positive Association Between Megasphaera and Survival of Chinese Patients With Pancreatic Ductal Adenocarcinomas
- (2022) Yu Huang et al. Frontiers in Immunology
- A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events
- (2022) Sangeeta Goswami et al. CANCER CELL
- Patient-derived micro-organospheres enable clinical precision oncology
- (2022) Shengli Ding et al. Cell Stem Cell
- Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC
- (2022) Joe Y Chang et al. LANCET ONCOLOGY
- Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
- (2022) Byoung Chul Cho et al. LANCET ONCOLOGY
- Androgen receptor activity in T cells limits checkpoint blockade efficacy
- (2022) Xiangnan Guan et al. NATURE
- Neoantigen quality predicts immunoediting in survivors of pancreatic cancer
- (2022) Marta Łuksza et al. NATURE
- LAG3 associates with TCR–CD3 complexes and suppresses signaling by driving co-receptor–Lck dissociation
- (2022) Clifford Guy et al. NATURE IMMUNOLOGY
- Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
- (2022) Karla A. Lee et al. NATURE MEDICINE
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
- (2022) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy
- (2022) Pavlos Msaouel et al. Science Translational Medicine
- Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
- (2022) Yunzhou Pu et al. Frontiers in Immunology
- Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
- (2022) Jens Huober et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
- (2022) Andrea Cercek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Network-based machine learning approach to predict immunotherapy response in cancer patients
- (2022) JungHo Kong et al. Nature Communications
- Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
- (2022) Jason A. Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
- (2022) Melissa L. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial
- (2022) Sungjune Kim et al. LANCET
- Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
- (2022) Elisabeth Livingstone et al. LANCET
- Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
- (2022) Sumanta Kumar Pal et al. LANCET
- Neoadjuvant relatlimab and nivolumab in resectable melanoma
- (2022) Rodabe N. Amaria et al. NATURE
- Reversible epigenetic alterations regulate class I HLA loss in prostate cancer
- (2022) Tamara S. Rodems et al. Communications Biology
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- (2022) Yifan Zhou et al. JOURNAL OF EXPERIMENTAL MEDICINE
- T cells specific for α-myosin drive immunotherapy-related myocarditis
- (2022) Margaret L. Axelrod et al. NATURE
- Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution
- (2022) Kerstin Thol et al. Genome Medicine
- VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy
- (2021) Long Yuan et al. TRENDS IN IMMUNOLOGY
- Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
- (2021) Julianne D. Twomey et al. AAPS Journal
- Understanding the impact of immune-mediated selection on lung cancer evolution
- (2021) Rachel Rosenthal et al. BRITISH JOURNAL OF CANCER
- A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells
- (2021) Sijin Cheng et al. CELL
- Understanding and treating the inflammatory adverse events of cancer immunotherapy
- (2021) Michael Dougan et al. CELL
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
- (2021) Diwakar Davar et al. SCIENCE
- Chemokines and the immune response to cancer
- (2021) Aleksandra J. Ozga et al. IMMUNITY
- Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
- (2021) Daniel J. Olson et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
- (2021) Nasser K Altorki et al. LANCET ONCOLOGY
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- (2021) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization
- (2021) Ana Rita Pombo Antunes et al. NATURE NEUROSCIENCE
- The Next Decade of Immune Checkpoint Therapy
- (2021) Padmanee Sharma et al. Cancer Discovery
- Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging
- (2021) Darci Phillips et al. Frontiers in Immunology
- Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer
- (2021) Tracy L. Rose et al. JOURNAL OF CLINICAL ONCOLOGY
- SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial
- (2021) Sacha I. Rothschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.
- (2021) Todd Michael Bauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- (2021) Enriqueta Felip et al. LANCET
- Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
- (2021) Chung-Han Lee et al. LANCET ONCOLOGY
- ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
- (2021) Thomas Powles et al. NATURE
- Clinical and therapeutic relevance of cancer-associated fibroblasts
- (2021) Yang Chen et al. Nature Reviews Clinical Oncology
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
- (2021) Lewis Au et al. CANCER CELL
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
- (2021) Golnaz Morad et al. CELL
- Interferon-Gamma–Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor–Colitis
- (2021) Sarah C. Sasson et al. GASTROENTEROLOGY
- Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study
- (2021) David M. O'Malley et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
- (2021) Lukas Kraehenbuehl et al. Nature Reviews Clinical Oncology
- Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
- (2021) Christine N. Spencer et al. SCIENCE
- Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions
- (2021) Alma Andersson et al. Nature Communications
- B cells are associated with survival and immunotherapy response in sarcoma
- (2020) Florent Petitprez et al. NATURE
- VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance
- (2020) Mohamed A. ElTanbouly et al. SCIENCE
- Biomarkers associated with beneficial PD-1 checkpoint blockade in non-small-cell lung cancer (NSCLC) identified using high-plex digital spatial profiling
- (2020) Jon Zugazagoitia et al. CLINICAL CANCER RESEARCH
- The CD47-SIRPα Immune Checkpoint
- (2020) Meike E.W. Logtenberg et al. IMMUNITY
- A conserved dendritic-cell regulatory program limits antitumour immunity
- (2020) Barbara Maier et al. NATURE
- Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer
- (2020) Sumit K. Subudhi et al. Science Translational Medicine
- CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
- (2020) Jerry B. Harvey et al. Frontiers in Immunology
- Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
- (2020) Adrienne M. Luoma et al. CELL
- TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy
- (2020) Martina Molgora et al. CELL
- A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma
- (2020) Fathima Zumla Cader et al. NATURE MEDICINE
- ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
- (2020) Sangeeta Goswami et al. Science Translational Medicine
- Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
- (2020) Padmanee Sharma et al. CANCER CELL
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- LAG-3: from molecular functions to clinical applications
- (2020) Takumi Maruhashi et al. Journal for ImmunoTherapy of Cancer
- TIGIT in cancer immunotherapy
- (2020) Joe-Marc Chauvin et al. Journal for ImmunoTherapy of Cancer
- Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
- (2020) Jeffrey C Thompson et al. Journal for ImmunoTherapy of Cancer
- Enhancing anti-tumour efficacy with immunotherapy combinations
- (2020) Funda Meric-Bernstam et al. LANCET
- Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
- (2020) Erez N. Baruch et al. SCIENCE
- WNT/β-catenin pathway activation correlates with immune exclusion across human cancers
- (2019) Jason J. Luke et al. CLINICAL CANCER RESEARCH
- Checkpoint inhibitors go viral
- (2019) Melanie Senior NATURE BIOTECHNOLOGY
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- The microbiome, cancer, and cancer therapy
- (2019) Beth A. Helmink et al. NATURE MEDICINE
- Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T Cell Response Against Immunosuppressive Tumors
- (2019) Miro K Viitala et al. CLINICAL CANCER RESEARCH
- KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer
- (2019) Wenting Liao et al. CANCER CELL
- Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
- (2019) V. Ellen Maher et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
- (2019) Abdullah Al Emran et al. TRENDS IN IMMUNOLOGY
- Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
- (2019) Davide Bedognetti et al. Journal for ImmunoTherapy of Cancer
- Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
- (2019) Jason Chesney et al. BRITISH JOURNAL OF CANCER
- Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Response
- (2019) Anu Sharma et al. CLINICAL CANCER RESEARCH
- CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
- (2019) Amira A. Barkal et al. NATURE
- Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression
- (2019) Atsunori Kamiya et al. NATURE NEUROSCIENCE
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Tumor neoantigens: from basic research to clinical applications
- (2019) Tao Jiang et al. Journal of Hematology & Oncology
- Neoantigen quality, not quantity
- (2019) Nicholas McGranahan et al. Science Translational Medicine
- Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy
- (2019) Shiping Jiao et al. CELL
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
- (2019) Sangeeta Goswami et al. NATURE MEDICINE
- IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development
- (2019) Amy Li et al. Cell Reports
- Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer
- (2018) Linnéa La Fleur et al. INTERNATIONAL JOURNAL OF CANCER
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
- (2018) Rebekka Weber et al. Frontiers in Immunology
- Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy
- (2018) Sangeeta Goswami et al. JOURNAL OF CLINICAL INVESTIGATION
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic role of myeloid-derived suppressor cells in cancers: a systematic review and meta-analysis
- (2018) Lisha Ai et al. BMC CANCER
- Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
- (2018) Yinghong Wang et al. NATURE MEDICINE
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
- (2016) Jiqing Sai et al. CLINICAL CANCER RESEARCH
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- The role of neoantigens in response to immune checkpoint blockade
- (2016) Nadeem Riaz et al. INTERNATIONAL IMMUNOLOGY
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
- (2016) Vincenzo Bronte et al. Nature Communications
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
- (2016) J. Liu et al. Cancer Discovery
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
- (2015) F. Skoulidis et al. Cancer Discovery
- Myeloid cells in the tumor microenvironment: Role of adenosine
- (2015) Silvana Morello et al. OncoImmunology
- VISTA Regulates the Development of Protective Antitumor Immunity
- (2014) I. Le Mercier et al. CANCER RESEARCH
- Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
- (2014) Xiaozhou Fan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Increased CD8+ T-cell Function following Castration and Immunization Is Countered by Parallel Expansion of Regulatory T Cells
- (2012) S. Tang et al. CANCER RESEARCH
- Regulation of TCR signalling by tyrosine phosphatases: from immune homeostasis to autoimmunity
- (2012) Stephanie M. Stanford et al. IMMUNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy
- (2011) T. Fu et al. CANCER RESEARCH
- Regulatory T cells and Foxp3
- (2011) Alexander Y. Rudensky IMMUNOLOGICAL REVIEWS
- T cells localized to the androgen-deprived prostate are TH1 and TH17 biased
- (2011) Matthew D. Morse et al. PROSTATE
- Control of Immunity by the TNFR-Related Molecule OX40 (CD134)
- (2010) Michael Croft Annual Review of Immunology
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
- (2010) B. C. Carthon et al. CLINICAL CANCER RESEARCH
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-
- (2010) M. Kraman et al. SCIENCE
- T Cell Activation
- (2009) Jennifer E. Smith-Garvin et al. Annual Review of Immunology
- The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
- (2009) J. Ozao-Choy et al. CANCER RESEARCH
- The significance of OX40 and OX40L to T-cell biology and immune disease
- (2009) Michael Croft et al. IMMUNOLOGICAL REVIEWS
- CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- (2008) C. I. Liakou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now